NephroPlus Secures SEBI Nod for Rs 353.4 Crore IPO
NephroPlus, India's largest dialysis services provider, has received SEBI approval for its IPO. The offering includes a fresh issue of Rs 353.4 crore and an offer for sale of 1.27 crore equity shares. The company plans to use the proceeds for expanding dialysis clinics in India, debt repayment, and general corporate purposes. NephroPlus operates in 5 countries, serves over 33,000 patients monthly, and owns 5,068 dialysis machines. The company projects a 20.09% CAGR in treatments between fiscal 2023 and 2025.
*this image is generated using AI for illustrative purposes only.
NephroPlus, operating under Nephrocare Health Services, has received approval from the Securities and Exchange Board of India (SEBI) for its Initial Public Offering (IPO). The Hyderabad-based dialysis services provider plans to raise funds through a combination of fresh issue and offer for sale (OFS).
IPO Structure
- Fresh Issue: Rs 353.4 crore
- Offer for Sale: 1.27 crore equity shares
Company Overview
NephroPlus claims to be:
- India's largest dialysis services provider
- 5th largest globally by number of treatments performed
- Operating across 5 countries
- Serving over 33,000 patients monthly
- Owner of 5,068 dialysis machines
Performance Metrics
- Over 3.3 million treatments performed
- Treatment growth: 20.09% CAGR between fiscal 2023 and 2025
IPO Proceeds Utilization
| Purpose | Amount (in Rs crore) |
|---|---|
| Capital expenditure for new dialysis clinics in India | 129.10 |
| Debt repayment | 136.00 |
| General corporate purposes | Remaining funds |
Offer for Sale Participants
The OFS includes shares from:
- Promoters
- Investcorp Private Equity Fund II
- Healthcare Parent Limited
- Investcorp Growth Opportunity Fund
- Other institutional investors
This IPO marks a significant milestone for NephroPlus, potentially fueling its expansion in the dialysis services sector. Investors should carefully review the company's financials and growth prospects before making investment decisions.
15
